PMID- 27083101
OWN - NLM
STAT- MEDLINE
DCOM- 20170216
LR  - 20170216
IS  - 1557-8607 (Electronic)
IS  - 0889-8561 (Linking)
VI  - 36
IP  - 2
DP  - 2016 May
TI  - Allergic Rhinitis: Mechanisms and Treatment.
PG  - 261-78
LID - S0889-8561(15)00115-0 [pii]
LID - 10.1016/j.iac.2015.12.004 [doi]
AB  - The prevalence of allergic rhinitis (AR) has been estimated at 10% to 40%, and 
      its economic burden is substantial. AR patients develop specific immunoglobulin E 
      (IgE) antibody responses to indoor and outdoor environmental allergens with 
      exposure over time. These specific IgE antibodies bind to high-affinity IgE 
      receptors on mast cells and basophils. Key outcome measures of therapeutic 
      interventions include rhinitis symptom control, rescue medication requirements, 
      and quality-of-life measures. A comprehensive multiple modality treatment plan 
      customized to the individual patient can optimize outcomes.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Bernstein, David I
AU  - Bernstein DI
AD  - Division of Immunology and Allergy, Department of Internal Medicine, University 
      of Cincinnati College of Medicine, Cincinnati, OH, USA. Electronic address: 
      bernstdd@ucmail.uc.edu.
FAU - Schwartz, Gene
AU  - Schwartz G
AD  - Division of Immunology and Allergy, Department of Internal Medicine, University 
      of Cincinnati College of Medicine, Cincinnati, OH, USA.
FAU - Bernstein, Jonathan A
AU  - Bernstein JA
AD  - Division of Immunology and Allergy, Department of Internal Medicine, University 
      of Cincinnati College of Medicine, Cincinnati, OH, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160310
PL  - United States
TA  - Immunol Allergy Clin North Am
JT  - Immunology and allergy clinics of North America
JID - 8805635
SB  - IM
MH  - Humans
MH  - Immunotherapy/standards/trends
MH  - *Rhinitis, Allergic/drug therapy/immunology
MH  - Rhinitis, Allergic, Seasonal/therapy
OTO - NOTNLM
OT  - Allergic rhinitis treatment
OT  - Intranasal antihistamines
OT  - Intranasal corticosteroids
OT  - Leukotrienes
OT  - Mechanisms
OT  - Subcutaneous immunotherapy
OT  - Treatment
EDAT- 2016/04/17 06:00
MHDA- 2017/02/17 06:00
CRDT- 2016/04/17 06:00
PHST- 2016/04/17 06:00 [entrez]
PHST- 2016/04/17 06:00 [pubmed]
PHST- 2017/02/17 06:00 [medline]
AID - S0889-8561(15)00115-0 [pii]
AID - 10.1016/j.iac.2015.12.004 [doi]
PST - ppublish
SO  - Immunol Allergy Clin North Am. 2016 May;36(2):261-78. doi: 
      10.1016/j.iac.2015.12.004. Epub 2016 Mar 10.